Motomura Hiraku, Matsushita Isao, Seki Eiko, Mine Hayato, Kimura Tomoatsu
Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan.
Int J Rheum Dis. 2014 Sep;17(7):749-54. doi: 10.1111/1756-185X.12227. Epub 2013 Nov 20.
To examine the inhibitory effect of tacrolimus on radiographic joint damage in patients with rheumatoid arthritis (RA).
Thirty-eight patients with RA resistant or intolerant to conventional disease-modifying anti-rheumatic drugs were administered tacrolimus and analyzed retrospectively. Disease activity and clinical response were evaluated by Disease Activity Score in 28 joints and C-reactive protein (DAS28-CRP) and European League Against Rheumatism (EULAR) response criteria. The progression of joint destruction was evaluated by an estimated yearly change in modified Total Sharp Score (mTSS).
Good or moderate response rate according to EULAR response criteria was seen in 63.2%, 63.2%, 73.7% and 65.8% of patients at 3, 6, 12, and 24 months, respectively. The rate of patients with low disease activity or remission reached 47.3% and 50.0% at 12 and 24 months, respectively. Progression of joint damage, evaluated as yearly change in mTSS (ΔmTSS), significantly decreased from 11.4 at baseline to 2.63 in the first year and 0.69 in the second year of tacrolimus treatment.
These findings suggest tacrolimus has the potential to inhibit progression of joint damage in established RA.
